<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:58:42Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6729083" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6729083</identifier>
        <datestamp>2019-09-12</datestamp>
        <setSpec>jimmthercanc</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id>
              <journal-title-group>
                <journal-title>Journal for Immunotherapy of Cancer</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2051-1426</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6729083</article-id>
              <article-id pub-id-type="pmcid">PMC6729083</article-id>
              <article-id pub-id-type="pmc-uid">6729083</article-id>
              <article-id pub-id-type="pmid">31488216</article-id>
              <article-id pub-id-type="publisher-id">706</article-id>
              <article-id pub-id-type="doi">10.1186/s40425-019-0706-x</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Bilusic</surname>
                    <given-names>Marijo</given-names>
                  </name>
                  <address>
                    <email>marijo.bilusic@nih.gov</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Heery</surname>
                    <given-names>Christopher R.</given-names>
                  </name>
                  <address>
                    <email>Christopher.Heery@bavarian-nordic.com</email>
                  </address>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Collins</surname>
                    <given-names>Julie M.</given-names>
                  </name>
                  <address>
                    <email>julie.collins@nih.gov</email>
                  </address>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Donahue</surname>
                    <given-names>Renee N.</given-names>
                  </name>
                  <address>
                    <email>renee.donahue@nih.gov</email>
                  </address>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Palena</surname>
                    <given-names>Claudia</given-names>
                  </name>
                  <address>
                    <email>palenac@mail.nih.gov</email>
                  </address>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Madan</surname>
                    <given-names>Ravi A.</given-names>
                  </name>
                  <address>
                    <email>madanr@mail.nih.gov</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Karzai</surname>
                    <given-names>Fatima</given-names>
                  </name>
                  <address>
                    <email>fatima.karzai@nih.gov</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mart√©</surname>
                    <given-names>Jennifer L.</given-names>
                  </name>
                  <address>
                    <email>jenn.marte@nih.gov</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Strauss</surname>
                    <given-names>Julius</given-names>
                  </name>
                  <address>
                    <email>julius.strauss@nih.gov</email>
                  </address>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gatti-Mays</surname>
                    <given-names>Margaret E.</given-names>
                  </name>
                  <address>
                    <email>margaret.gatti-mays@nih.gov</email>
                  </address>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Schlom</surname>
                    <given-names>Jeffrey</given-names>
                  </name>
                  <address>
                    <email>schlomj@mail.nih.gov</email>
                  </address>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6569-2912</contrib-id>
                  <name>
                    <surname>Gulley</surname>
                    <given-names>James L.</given-names>
                  </name>
                  <address>
                    <email>gulleyj@mail.nih.gov</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2297 5165</institution-id><institution-id institution-id-type="GRID">grid.94365.3d</institution-id><institution>Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, </institution><institution>National Institutes of Health, </institution></institution-wrap>Bethesda, MD USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2297 5165</institution-id><institution-id institution-id-type="GRID">grid.94365.3d</institution-id><institution>Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, </institution><institution>National Institutes of Health, </institution></institution-wrap>Bethesda, MD USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2297 5165</institution-id><institution-id institution-id-type="GRID">grid.94365.3d</institution-id><institution>Medical Oncology Service, Center for Cancer Research, National Cancer Institute, </institution><institution>National Institutes of Health, </institution></institution-wrap>Bethesda, MD USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.429964.4</institution-id><institution>Precision Biosciences, </institution></institution-wrap>Durham, NC USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>5</day>
                <month>9</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>5</day>
                <month>9</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2019</year>
              </pub-date>
              <volume>7</volume>
              <elocation-id>240</elocation-id>
              <history>
                <date date-type="received">
                  <day>9</day>
                  <month>4</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>7</day>
                  <month>8</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>¬© The Author(s). 2019</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition, and recruitment of myeloid-derived suppressor cells. Studies have demonstrated that high serum IL-8 levels correlate with poor prognosis in many malignant tumors. Preclinical studies have shown that IL-8 blockade may reduce mesenchymal features in tumor cells, making them less resistant to treatment.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">Fifteen patients with metastatic or unresectable locally advanced solid tumors were enrolled in this 3‚Äâ+‚Äâ3 dose-escalation trial at four dose levels (4, 8, 16, or 32‚Äâmg/kg). HuMax-IL8 was given IV every 2‚Äâweeks, and patients were followed for safety and immune monitoring at defined intervals up to 52‚Äâweeks.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">All enrolled patients (five chordoma, four colorectal, two prostate, and one each of ovarian, papillary thyroid, chondrosarcoma, and esophageal) received at least one dose of HuMax-IL8. Eight patients had received three or more prior lines of therapy and five patients had received prior immunotherapy. Treatment-related adverse events occurred in five patients (33%), mostly grade 1. Two patients receiving the 32‚Äâmg/kg dose had grade 2 fatigue, hypophosphatemia, and hypersomnia. No dose-limiting toxicities were observed, and maximum tolerated dose was not reached. Although no objective tumor responses were observed, 11 patients (73%) had stable disease with median treatment duration of 24‚Äâweeks (range, 4‚Äì54‚Äâweeks). Serum IL-8 was significantly reduced on day 3 of HuMax-IL8 treatment compared to baseline (<italic>p</italic>‚Äâ=‚Äâ0.0004), with reductions in IL-8 seen at all dose levels.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p id="Par4">HuMax-IL8 is safe and well-tolerated. Ongoing studies are evaluating the combination of IL-8 blockade and other immunotherapies.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p id="Par5">NCTN, NCT02536469. Registered 23 August 2015, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02536469?term=NCT02536469&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02536469?term=NCT02536469&amp;rank=1</ext-link>.</p>
                </sec>
                <sec>
                  <title>Electronic supplementary material</title>
                  <p>The online version of this article (10.1186/s40425-019-0706-x) contains supplementary material, which is available to authorized users.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Interleukin-8 (IL-8)</kwd>
                <kwd>Metastatic cancer</kwd>
                <kwd>Solid tumor</kwd>
                <kwd>HuMax-IL8</kwd>
                <kwd>BMS-986253</kwd>
                <kwd>Monoclonal antibody</kwd>
                <kwd>Immunotherapy</kwd>
                <kwd>Clinical trial</kwd>
                <kwd>Immune assays</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id>
                      <institution>National Cancer Institute</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>¬© The Author(s) 2019</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Background</title>
              <p id="Par25">Interleukin-8 (IL-8) is a pro-inflammatory chemokine from the CXC family; it is also known as CXCL8. It mediates biologic effects by binding to two cell-surface G protein-coupled receptors, IL-8RA (CXCR1) and IL-8RB (CXCR2), which are expressed on neutrophils, monocytes, endothelial cells, and cancer cells [<xref ref-type="bibr" rid="CR1">1</xref>‚Äì<xref ref-type="bibr" rid="CR4">4</xref>]. Expression of IL-8 is regulated by chemical and environmental stresses such as chemotherapies and hypoxia and by inflammatory signals [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. IL-8 mediates the activation and chemotaxis of immune cells leading to chronic inflammation [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. IL-8 is also frequently overexpressed in many human carcinomas, including breast, colon, cervical, gastric, lung, and ovarian [<xref ref-type="bibr" rid="CR9">9</xref>‚Äì<xref ref-type="bibr" rid="CR13">13</xref>]. Studies have shown a direct correlation between serum IL-8 levels and disease progression [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. IL-8 has also been linked to tumor stem cell-like properties or ‚Äústemness,‚Äù including self-renewal, differentiation, and proliferative potential. Breast cancer cells with elevated aldehyde dehydrogenase activity, a marker of breast cancer stem cells, express high levels of IL-8 receptor (IL-8R) [<xref ref-type="bibr" rid="CR16">16</xref>]. IL-8 functions in both a paracrine and autocrine mode within the tumor microenvironment (TME) to foster tumor progression, invasiveness, and metastasis [<xref ref-type="bibr" rid="CR4">4</xref>]. IL-8 signaling is known to influence the TME and promote cancer progression by (a) inducing the angiogenic response of endothelial cells, (b) recruiting neutrophils and myeloid-derived suppressor cells (MDSCs) to the tumor bed, (c) facilitating the proliferation, survival, and migration of tumor cells, and (d) promoting epithelial-mesenchymal transition (EMT) [<xref ref-type="bibr" rid="CR17">17</xref>‚Äì<xref ref-type="bibr" rid="CR22">22</xref>].</p>
              <p id="Par26">Induction of the IL-8/IL-8R axis has also been shown to increase levels of brachyury, a transcription factor overexpressed in a variety of carcinomas but absent in the majority of normal adult tissues [<xref ref-type="bibr" rid="CR23">23</xref>]. Brachyury has been shown to regulate EMT in human carcinoma cells and to induce mechanisms of tumor resistance to chemotherapy and radiation [<xref ref-type="bibr" rid="CR24">24</xref>‚Äì<xref ref-type="bibr" rid="CR26">26</xref>]. Conversely, antibody blockade of IL-8/IL-8R markedly reduces the expression of mesenchymal markers, decreases recruitment of MDSCs, and enhances immune-mediated lysis of tumor cells [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. These data suggest that pharmacologic inhibition of IL-8 is a rational approach for the treatment of a variety of malignancies.</p>
              <p id="Par27">HuMax-IL8 (previously known as BMS-986253) is a fully human IgG1 kappa monoclonal antibody that binds to free IL-8 [<xref ref-type="bibr" rid="CR4">4</xref>]. The safety and efficacy of HuMax-IL8 monotherapy was tested in a phase I/II clinical trial in patients with palmoplantar pustulosis, a rare chronic inflammatory skin disorder. The drug was well tolerated and effective in reducing disease activity at doses of 0.15 to 8‚Äâmg/kg IV. The maximum tolerated dose (MTD) was not reached. The antibody had a half-life of approximately 11‚Äâdays [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
              <p id="Par28">This phase I study evaluated the safety and tolerability of HuMax-IL8, as well as changes in serum IL-8 levels, peripheral immune subsets, and circulating tumor cells (CTCs) in patients with incurable metastatic or unresectable solid tumors. This is the first study to evaluate this agent in patients with cancer and this study utilized higher doses of the agent than had been previously tested in any disease.</p>
            </sec>
            <sec id="Sec2">
              <title>Patients and methods</title>
              <sec id="Sec3">
                <title>Eligibility</title>
                <p id="Par29">Eligible patients had incurable metastatic or unresectable, locally advanced malignant solid tumors that were evaluable or measurable. They must have completed or had disease progression on at least one prior line of disease-appropriate therapy for metastatic disease, or not be a candidate for therapy with proven efficacy for their disease. There had to be a minimum of 4‚Äâweeks from any prior chemotherapy, immunotherapy (6‚Äâweeks if immune checkpoint inhibitor), and/or radiation<bold>,</bold> but patients with colorectal cancer were allowed to continue on maintenance capecitabine and/or bevacizumab. Patients were required to be ‚â•18‚Äâyears of age, have an Eastern Cooperative Oncology Group (ECOG) performance status of ‚â§1, no other malignancies within 12‚Äâmonths, no significant medical illnesses or autoimmune diseases, and acceptable hematologic parameters and organ function. No local or systemic steroids except for physiologic replacement doses were allowed within 2‚Äâweeks of enrollment. Patients were excluded if they had untreated central nervous system metastases or local treatment of brain metastases within the previous 6‚Äâmonths, HIV, or chronic hepatitis B or C infection.</p>
              </sec>
              <sec id="Sec4">
                <title>Assessment of toxicities</title>
                <p id="Par30">Toxicity was evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. A dose-limiting toxicity (DLT) was defined as any grade‚Äâ‚â•‚Äâ4 hematologic toxicity or any grade‚Äâ‚â•‚Äâ3 nonhematologic toxicity, with minor exceptions, or any grade‚Äâ‚â•‚Äâ3 allergic reaction or autoimmune reaction that was definitely, probably, or possibly related to the administration of HuMax-IL8.</p>
              </sec>
              <sec id="Sec5">
                <title>Study design</title>
                <p id="Par31">This was a single-institution, open-label, phase I clinical study intended to determine the safety and MTD of HuMax-IL8 at four dose levels (4, 8, 16, and 32‚Äâmg/kg) IV every 2‚Äâweeks with each cycle being 28‚Äâdays. Accrual of up to 24 patients in the dose-escalation phase and an additional 20 patients in the dose-expansion phase were initially planned.</p>
                <p id="Par32">Enrollment in each dose cohort proceeded in the standard 3‚Äâ+‚Äâ3 scheme with sequential cohorts of patients (three to six patients per cohort) (Fig.¬†<xref rid="Fig1" ref-type="fig">1</xref>). The decision to escalate to the next dose level was based on the observation of DLTs during the 28-day period following the first dose of HuMax-IL8. The MTD was defined as one dose level below the maximum administered dose.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Trial schema. Trial schema with dose-escalation strategy</p></caption><graphic xlink:href="40425_2019_706_Fig1_HTML" id="MO1"/></fig></p>
                <p id="Par33">Tumor responses were evaluated by CT of the chest/abdomen/pelvis (with optional MRI or PET scan) at baseline and then every 2‚Äâmonths. Treatment was continued until disease progression, unacceptable adverse events (AEs), or withdrawal from the study. The safety and efficacy of the study drug were assessed until the end of treatment or for a maximum of 52‚Äâweeks.</p>
                <p id="Par34">Response to treatment was measured by combined immune-related response criteria (irRC) and RECIST v1.1. The main modifications from RECIST 1.1 were (a) a requirement for confirmation of both progression and response by imaging at least 4‚Äâweeks after initial imaging and (b) not automatically calling the appearance of new lesions progressive disease if the total measurable tumor burden had not met criteria for progressive disease. In the spirit of the irRC, any new lesions in these subjects required confirmation of the new lesion on repeat imaging at least 4‚Äâweeks later to ensure that new lesions were not immune-related phenomena [<xref ref-type="bibr" rid="CR28">28</xref>].</p>
              </sec>
              <sec id="Sec6">
                <title>Immune assays</title>
                <p id="Par35">Blood samples for immune-cell assessment were collected at baseline and on days 3 and 15 of cycle 1, prior to cycles 2 and 3, and then every other cycle. Blood samples for analysis of CTCs were collected at baseline, prior to cycles 2 and 3, and then every other cycle (for details see Additional¬†file¬†1).</p>
              </sec>
              <sec id="Sec7">
                <title>Statistical analysis</title>
                <p id="Par36">Summary statistics were used to describe demographic data and baseline performance status characteristics. Results of safety evaluations were tabulated and displayed by dose level. Only exploratory statistical analyses were performed due to the limited number of subjects receiving each dose level. Descriptive statistics were examined for indications of dose-related toxicity. Immunological parameters were mainly analyzed descriptively and displayed in graphic format using GraphPad Prism (GraphPad Software, La Jolla, CA). For changes in peripheral immune subset and cytokine analyses, <italic>p</italic> values were calculated using the Wilcoxon matched pairs signed rank test. Subsets with a potentially biologically relevant change were defined as those with a <italic>p</italic>‚Äâ&lt;‚Äâ0.05, majority of patients &gt;‚Äâ25% change, differences in medians of pre- vs. post-therapy &gt;‚Äâ0.01% of peripheral blood mononuclear cells (PBMCs), and a frequency‚Äâ&gt;‚Äâ0.01% of PBMCs. The Mann-Whitney test was used to evaluate differences in immune subsets at baseline. Fisher‚Äôs exact test was used to evaluate the proportion of patients with IL-8 levels under a given threshold.</p>
              </sec>
            </sec>
            <sec id="Sec8">
              <title>Results</title>
              <sec id="Sec9">
                <title>Patient population</title>
                <p id="Par37">Fifteen patients were enrolled between August 2015 and May 2016 at the National Cancer Institute in Bethesda, Maryland. Five patients had chordoma, four had colorectal cancer, two had prostate cancer, and one each had ovarian, papillary thyroid, chondrosarcoma, and esophageal cancer. The patients were predominantly white (80%) with a mean age of 59.7‚Äâyears (range 39‚Äì73). Eight patients had received three or more prior lines of therapy. Prior immunotherapy regimens ranged from 0 to 3 (median 0), which included therapeutic cancer vaccines (5 patients), cytokines (2 patients), and checkpoint inhibitors (2 patients). The median treatment duration was 24‚Äâweeks (range, 4‚Äì54‚Äâweeks). Baseline characteristics are summarized in Additional¬†file¬†<xref rid="MOESM1" ref-type="media">1</xref>: Table S1.</p>
              </sec>
              <sec id="Sec10">
                <title>Safety</title>
                <p id="Par38">Safety and efficacy were assessed until the end of treatment or for a maximum of 52‚Äâweeks. No DLTs were observed and no severe adverse events (SAEs) related to treatment with HuMax-IL8 occurred. MTD was not identified through 32‚Äâmg/kg, supporting 32‚Äâmg/kg of HuMax-IL8 IV every 2‚Äâweeks as the recommended phase II dose. Grade 1 or 2 treatment-related AEs occurred in five patients (Table¬†<xref rid="Tab1" ref-type="table">1</xref>).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Treatment-related adverse events</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Dose (mg/kg)</th><th>Grade 1, N (%)</th><th>Grade 2, N (%)</th></tr></thead><tbody><tr><td>Nausea</td><td>4 and 8</td><td>2 (13.3)</td><td>0</td></tr><tr><td>Headache</td><td>4</td><td>1 (6.7)</td><td>0</td></tr><tr><td>Chills</td><td>8</td><td>1 (6.7)</td><td>0</td></tr><tr><td>Throat tightness</td><td>8</td><td>1 (6.7)</td><td>0</td></tr><tr><td>Decreased WBC</td><td>16</td><td>1 (6.7)</td><td>0</td></tr><tr><td>Fatigue</td><td>32</td><td>1 (6.7)</td><td>2 (13.3)</td></tr><tr><td>Constipation</td><td>32</td><td>1 (6.7)</td><td>0</td></tr><tr><td>Hypersomnia</td><td>32</td><td>0</td><td>2 (13.3)</td></tr><tr><td>Hypophosphatemia</td><td>32</td><td>0</td><td>2 (13.3)</td></tr></tbody></table><table-wrap-foot><p>All adverse events at least possibly attributed to study drug are shown. There were no grade 3 or grade 4 treatment-related adverse events. Adverse event grade is according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0</p><p><italic>kg</italic> kilogram</p><p><italic>mg</italic> milligram</p><p><italic>WBC</italic> white blood cell</p></table-wrap-foot></table-wrap></p>
                <p id="Par39">Two SAEs were reported in one patient receiving 4‚Äâmg/kg of HuMax-IL8, and five grade 3 SAEs were reported in three patients receiving 8‚Äâmg/kg, 16‚Äâmg/kg, and 32/mg, respectively. The grade 3 SAEs were pain, increased blood alkaline phosphatase, abdominal infection, hyponatremia, and a fall. The most common AEs were constipation (33.3%), nausea (26.7%) and anemia (26.7%). AEs leading to discontinuation of HuMax-IL8 were reported in three patients (20%); they included grade 3 increased blood alkaline phosphatase in one patient, grade 2 increased blood creatinine and grade 3 hypertension in one patient, and grade 3 fall and back pain in one patient, none of which were considered to be related to the study drug.</p>
              </sec>
              <sec id="Sec11">
                <title>Pharmacokinetics</title>
                <p id="Par40">Noncompartmental analysis characterized the pharmacokinetic parameters for HuMax-IL8. Maximum concentrations were observed within 1‚Äì5‚Äâh across the doses evaluated following the 1-h infusion. Both the maximum concentration (C<sub>max</sub>) and area under the curve geometric mean of HuMax-IL8 demonstrated linear increases in exposure for the tested doses (Additional¬†file¬†<xref rid="MOESM1" ref-type="media">1</xref>: Table S2). Following multiple (e.g., every 2‚Äâweeks) administration of HuMax-IL8 at 4, 8, 16, and 32‚Äâmg/kg doses, steady-state pharmacokinetics had not been fully achieved by day 15 after two doses; hence there is insufficient data to report clearance and half-life using the noncompartmental method. Time dependencies in exposure have not been determined to date.</p>
              </sec>
              <sec id="Sec12">
                <title>Response to therapy</title>
                <p id="Par41">Evaluation of clinical benefit (best overall response and progression-free survival) was an exploratory objective in this study. Nine patients with stable disease came off study due to patient preference (the majority opting for another line of therapy), and six came off study due to disease progression. As shown in Table¬†<xref rid="Tab2" ref-type="table">2</xref>, best response (per RECIST v1.1) was stable disease observed in 11 patients (73.3%). The progression-free survival rate at 5.5‚Äâmonths was 53.3%. Time on study ranged from 2 to 13‚Äâmonths.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Best overall response</p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="7">a</td></tr><tr><td/><td><p>DL 1</p><p>4‚Äâmg/kg</p><p><italic>N</italic>‚Äâ=‚Äâ3</p></td><td><p>DL 2</p><p>8‚Äâmg/kg</p><p><italic>N‚Äâ=</italic>¬†3</p></td><td><p>DL 3</p><p>16‚Äâmg/kg</p><p><italic>N</italic>‚Äâ=‚Äâ3</p></td><td><p>DL 4</p><p>32‚Äâmg/kg</p><p><italic>N</italic>‚Äâ=‚Äâ6</p></td><td colspan="2"><p>Overall</p><p><italic>N</italic>‚Äâ=‚Äâ15</p></td></tr><tr><td>Stable disease (N, %)</td><td>3 (100%)</td><td>2 (67%)</td><td>2 (67%)</td><td>4 (67%)</td><td colspan="2">11 (73%)</td></tr><tr><td>Progressive disease (N, %)</td><td>0 (0%)</td><td>1 (33%)</td><td>1 (33%)</td><td>2 (33%)</td><td colspan="2">4 (27%)</td></tr><tr><td colspan="7">b</td></tr><tr><td>Patient #</td><td>Tumor type</td><td>Dose (mg/kg)</td><td>Time on study (months)*</td><td>Best response</td><td>Off treatment reason</td><td>IL-8 level decrease</td></tr><tr><td>1</td><td>Colorectal</td><td>4</td><td>3.5</td><td>SD</td><td>Patient choice</td><td/></tr><tr><td>2</td><td>Prostate</td><td>4</td><td>2</td><td>SD</td><td>Patient choice</td><td>x</td></tr><tr><td>3</td><td>Chordoma</td><td>4</td><td>8</td><td>SD</td><td>Patient choice</td><td/></tr><tr><td>4</td><td>Chordoma</td><td>8</td><td>13</td><td>SD</td><td>Patient choice</td><td/></tr><tr><td>5</td><td>Colorectal</td><td>8</td><td>1.5</td><td>PD</td><td>Progression</td><td/></tr><tr><td>6</td><td>Esophageal</td><td>8</td><td>7</td><td>SD</td><td>Progression</td><td>x</td></tr><tr><td>7</td><td>Chondrosarcoma</td><td>16</td><td>1</td><td>PD</td><td>Progression</td><td>x</td></tr><tr><td>8</td><td>Chordoma</td><td>16</td><td>5.5</td><td>SD</td><td>Progression</td><td/></tr><tr><td>9</td><td>Chordoma</td><td>16</td><td>5.5</td><td>SD</td><td>Patient choice</td><td>x</td></tr><tr><td>10</td><td>Papillary thyroid</td><td>32</td><td>5.5</td><td>SD</td><td>Patient choice</td><td>x</td></tr><tr><td>11</td><td>Colorectal</td><td>32</td><td>4.5</td><td>SD</td><td>Patient choice</td><td>x</td></tr><tr><td>12</td><td>Prostate</td><td>32</td><td>8</td><td>SD</td><td>Patient choice</td><td>x</td></tr><tr><td>13</td><td>Colorectal</td><td>32</td><td>7</td><td>SD</td><td>Patient choice</td><td>x</td></tr><tr><td>14</td><td>Ovarian</td><td>32</td><td>1.5</td><td>PD</td><td>Progression</td><td>x</td></tr><tr><td>15</td><td>Chordoma</td><td>32</td><td>2</td><td>PD</td><td>Progression</td><td>x</td></tr></tbody></table><table-wrap-foot><p>Best overall response. <bold>a</bold> Best overall response by dose level and overall are shown. <bold>b</bold> Responses are shown by tumor type and dose level in addition to time on study and reason for withdrawal from study treatment. Three patients had adverse events leading to their decision to come off the study. Decreases in IL-8 are also noted</p><p><italic>DL</italic> dose level; <italic>IL-8</italic> interleukin-8; <italic>SD</italic> stable disease; <italic>PD</italic> progressive disease</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec13">
                <title>Immune assays</title>
                <p id="Par42">Reductions in serum IL-8 levels were observed at all dose levels (Fig.¬†<xref rid="Fig2" ref-type="fig">2</xref>). Serum IL-8 was significantly reduced on day 3 after HuMax-IL8 compared to baseline (<italic>p</italic>‚Äâ=‚Äâ0.0004). Overall, 10/15 (67%) patients experienced a decrease in IL-8 levels, while those without a decrease in IL-8 had lower IL-8 levels at baseline (&lt;‚Äâ25‚Äâpg/mL). Prior to therapy, 11/15 (73.3%) patients had IL-8 levels &gt;‚Äâ10‚Äâpg/mL, while on day 3 after HuMax-IL8 only 3/15 (20%) patients had IL-8 levels &gt;‚Äâ10‚Äâpg/mL (<italic>p</italic>‚Äâ=‚Äâ0.0092). There was a trend toward a prolonged reduction in IL-8 levels at the highest dose level (32‚Äâmg/kg), which was associated with time on study, with 4/6 patients maintaining IL-8 levels lower than baseline for at least 112‚Äâdays. No significant changes were noted in the additional cytokines (IFN-Œ≥, IL-10, IL-12p70, IL-1b, IL-2, IL-6, or TNF-Œ±) or soluble factors (sCD27 and sCD40L) examined.
<fig id="Fig2"><label>Fig. 2</label><caption><p>Serum IL-8 levels pre- and post-treatment with HuMax-IL8. The human IL-8 ELISA kit was used to measure free serum IL-8 levels. Reductions in serum IL-8 levels were observed at all dose levels and were significantly reduced on day 3 compared to pre-treatment (<italic>p</italic>‚Äâ=‚Äâ0.0004)</p></caption><graphic xlink:href="40425_2019_706_Fig2_HTML" id="MO2"/></fig></p>
                <p id="Par43">In this study, we also analyzed 123 different immune cell subsets in PBMCs prior to therapy (day 1) and on days 3, 15, 29, 56, and 112 of therapy where samples were available (Additional¬†file¬†<xref rid="MOESM1" ref-type="media">1</xref>: Table S3). There were no statistically significant changes in any immune subsets post- vs. pre-therapy at any of the time points evaluated. There were also trends in the change of specific subsets after therapy and best overall response; patients with progressive disease experienced decreases in CD4+ T cells, CD4+ T cells expressing Tim3, CD8+ T cells, CD8 T cells expressing CTLA4, central memory CD8+ T cells, B cells, B cells expressing PD-L1, and regulatory T cells (Tregs).</p>
                <p id="Par44">Thirty-nine samples from 13 patients were analyzed using Epic Science‚Äôs CTC enumeration assay; three samples were not evaluable due to DAPI &lt;‚Äâ1.5 million. Prior to therapy, CTCs (‚â• 1 CTC/mL) were detected in 6/12 evaluable patients (Additional¬†file¬†<xref rid="MOESM1" ref-type="media">1</xref>: Figure S1a); nine of these patients were also evaluated for CTCs after HuMax-IL8, and CTCs were notably decreased in two of them (#3 and #7). CTCs decreased in patient #3 from 12.3 CTCs/mL prior to therapy to 1 CTC/mL on day 15, and were undetectable on days 30, 56, and 84. In patient #7, CTCs decreased from 21.8 CTCs/mL prior to therapy to 2.3 CTCs/mL on day 56; the CTCs observed after therapy demonstrated nuclear fragmentation or condensation characteristic of apoptosis (Additional¬†file¬†<xref rid="MOESM1" ref-type="media">1</xref>: Figure S1b).</p>
              </sec>
            </sec>
            <sec id="Sec14">
              <title>Discussion</title>
              <p id="Par45">IL-8 is overexpressed in multiple cancer types where it promotes the acquisition of mesenchymal features, stemness, resistance to therapies, and the recruitment of immune-suppressive cells to the tumor site. Through an autocrine feedback loop, IL-8 maintains the mesenchymal phenotype of tumor cells by further upregulating IL-8 and IL-8R, as well as inducing adjacent cells to undergo EMT in a paracrine mode within the tumor TME [<xref ref-type="bibr" rid="CR4">4</xref>]. Studies in preclinical models and clinical trials have shown that antibody blockade of IL-8 produces positive effects in both non-malignant inflammatory conditions and cancer [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. We have previously shown that HuMax-IL8 can revert mesenchymalization in triple negative breast cancer models both in vitro and in vivo as well as significantly decrease the recruitment of polymorphonuclear MDSCs at the tumor site, an effect substantiated when used in combination with docetaxel. HuMax-IL8 was also shown to enhance the susceptibility of breast cancer cells to immune-mediated lysis with natural killer (NK) and antigen-specific T cells in vitro, thus providing preclinical rationale for using HuMax-IL8 in combination with chemotherapy or immune-based therapies [<xref ref-type="bibr" rid="CR27">27</xref>].</p>
              <p id="Par46">This is the first trial to investigate the effects of IL-8 blockade in patients with advanced or metastatic solid tumors. The primary endpoints were met as there were no DLTs and MTD was not reached. HuMax-IL8 is a well-tolerated drug with an acceptable safety profile for further clinical development. This trial was not powered to evaluate time to progression or overall survival. Since this trial enrolled multiple tumor types, it is difficult to compare these values to historical controls. Although no patients had an objective response, 73.3% achieved stable disease as best overall response and 53.3% remained progression-free for at least 5.5‚Äâmonths, indicating some patients may have derived clinical benefit. The majority of patients were heavily pretreated and it is possible that observed disease stability is characteristic of their slow-progressing disease. Nine patients with stable disease came off study in order to start another line of therapy.</p>
              <p id="Par47">Secondary and exploratory analyses evaluated changes in cytokines, immune cells, and CTCs associated with IL-8 blockade. Decreases in serum IL-8 levels were seen at all dose levels, with prolonged decreases at higher dose levels associated with a longer time on study. Several patients on this trial had surprisingly low IL-8 levels at baseline, which may make the data difficult to interpret. In addition, IL-8 levels were only measured every 2‚Äâweeks (prior to the next dose) except in cycle 1 during which IL-8 levels were measured at baseline and again on day 3, which helps explain the significant decrease in IL-8 levels noted only after the first dose. It is possible that similar serum IL-8 reductions occurred after subsequent doses but were not captured due to the timing of blood sample collection. It is also possible that although no significant changes were seen within the 123 immune cell subsets evaluated in PBMCs, this does not accurately reflect changes occurring within the tumors themselves or maybe IL<bold>-</bold>8 inhibition alone is insufficient to meaningfully affect immune cell subsets. No biopsies were required in this phase I study, so this information remains unknown. There were no changes in MDSCs or neutrophils in peripheral blood. CTCs did not correlate with patient outcomes. Heterogeneity of patient and tumor characteristics also makes the immune assays and CTCs difficult to interpret.</p>
              <p id="Par48">The dose-expansion phase of this trial was not conducted due to a change in the development strategy, unrelated to safety, following the decision to evaluate potential synergetic combination strategies given the safety and potential clinical benefit seen with monotherapy and preclinical rationale. Preclinical studies have also shown that inhibition of the IL-8/IL-8R pathway in a mouse sarcoma model could work synergistically with checkpoint inhibition as a means of decreasing immunosuppression within the TME [<xref ref-type="bibr" rid="CR17">17</xref>]. In small cohorts of patients with melanoma and non-small cell lung cancer, decreases in serum IL-8 levels have been associated with response to anti-PD-1 therapy [<xref ref-type="bibr" rid="CR29">29</xref>]. In the patients who responded to anti-PD-1 therapy there was a significant decrease in serum IL-8 levels, and at the time of progression there was a significant increase. Early changes in serum IL-8 levels (2‚Äì4‚Äâweeks after treatment initiation) were strongly associated with response and longer overall survival. There is an ongoing phase I/II clinical trial evaluating BMS-986253 plus nivolumab in patients with advanced malignancies (NCT03400332). Other therapeutic combinations also demonstrate potential. IL-8 signaling has been implicated in regulating the transcriptional activity of the androgen receptor, underpinning the transition to an androgen-independent proliferation of prostate cancer cells [<xref ref-type="bibr" rid="CR30">30</xref>]. In addition, stress- and drug-induced IL-8 signaling has been shown to confer chemotherapeutic resistance in cancer cells. Therefore, inhibiting the effects of IL-8 signaling may be a significant therapeutic intervention in targeting the TME [<xref ref-type="bibr" rid="CR3">3</xref>], and combinations with androgen blockade, chemotherapy, and other agents could be explored. A phase I/II clinical trial is evaluating intermittent androgen-deprivation therapy plus nivolumab with and without BMS-986253 in men with hormone-sensitive prostate cancer (NCT03689699), which may help assess the interaction of androgen and IL-8. IL-8 blockade may also have a role as an adjunct to cancer therapy to decrease rash associated with epidermal growth factor receptor (EGFR) inhibitors. A study showed that concomitant local repeat doses of a neutralizing human antibody against IL-8 reduced rash in patients receiving EGFR inhibitors, likely due to decreased neutrophil chemotaxis with the decrease in IL-8 signaling [<xref ref-type="bibr" rid="CR31">31</xref>]. The acceptable safety profile and its potential for combination with different agents make HuMax-IL8 (BMS-986253) a promising agent for ongoing and future studies.</p>
            </sec>
            <sec id="Sec15">
              <title>Conclusions</title>
              <p id="Par49">HuMax-IL8 monotherapy is well tolerated and associated with significant decreases in serum IL-8 across all doses tested. Prolonged decreases of serum IL-8 levels were observed at higher doses of HuMax-IL-8 and were associated with a longer time on study. These data have informed combining this drug with checkpoint inhibitors and other therapies to evaluate the potential for synergetic activity in selected patient populations.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Additional file</title>
              <sec id="Sec16">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="40425_2019_706_MOESM1_ESM.docx">
                      <label>Additional file 1:</label>
                      <caption>
                        <p><bold>Table S1.</bold> Patient demographics. <bold>Table S2.</bold> Pharmacokinetic analyses. <bold>Table S3.</bold> Immune subset analyses<bold>. Fig. S1</bold> Circulating tumor cells (CTC). <bold>a</bold> Twelve patients had evaluable whole blood samples for CTC analysis. Two patients had CTCs &gt; 10 CTC/mL at baseline, which then decreased significantly. <bold>b</bold> The immunofluorescence image shows that in patient #7, the CTCs remaining at progression were apoptotic. (DOCX 483 kb)</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>AEs</term>
                  <def>
                    <p id="Par6">adverse events</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CI</term>
                  <def>
                    <p id="Par7">confidence interval</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CTCs</term>
                  <def>
                    <p id="Par8">circulating tumor cells</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DLT</term>
                  <def>
                    <p id="Par9">dose-limiting toxicity</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ECOG</term>
                  <def>
                    <p id="Par10">Eastern Cooperative Oncology Group</p>
                  </def>
                </def-item>
                <def-item>
                  <term>EGFR</term>
                  <def>
                    <p id="Par11">epidermal growth factor receptor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>EMT</term>
                  <def>
                    <p id="Par12">epithelial-mesenchymal transition</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IL-8</term>
                  <def>
                    <p id="Par13">Interleukin-8</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IL-8R</term>
                  <def>
                    <p id="Par14">IL-8 receptor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>irRC</term>
                  <def>
                    <p id="Par15">immune-related response criteria</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MDSCs</term>
                  <def>
                    <p id="Par16">myeloid-derived suppressor cells</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MTD</term>
                  <def>
                    <p id="Par17">maximum tolerated dose</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NK</term>
                  <def>
                    <p id="Par18">natural killer</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PBMCs</term>
                  <def>
                    <p id="Par19">peripheral blood mononuclear cells</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PD-1</term>
                  <def>
                    <p id="Par20">programmed cell death-1</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RECIST</term>
                  <def>
                    <p id="Par21">Response Evaluation Criteria in Solid Tumors</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SAEs</term>
                  <def>
                    <p id="Par22">severe adverse events</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TME</term>
                  <def>
                    <p id="Par23">tumor microenvironment</p>
                  </def>
                </def-item>
                <def-item>
                  <term>Tregs</term>
                  <def>
                    <p id="Par24">regulatory T cells</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher‚Äôs Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
              <fn>
                <p>Marijo Bilusic and Christopher R. Heery contributed equally to this work.</p>
              </fn>
            </fn-group>
            <ack>
              <p>The authors would like to thank the patients and research staff that made this trial possible.</p>
              <p>Also, the authors would like to thank the Morgan Gargulak for technical assistance with assays, Maarten de Chateau, M.D., Ph.D, the co-founder of Cormorant Pharmaceuticals, for trial input, and Debra Weingarten and Bonnie Casey for editorial assistance.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Authors‚Äô contributions</title>
              <p>CH, JS, and JG designed the study. MB, CH, RM, FK, JSt, and JG treated patients and performed the clinical data acquisition. MB, JC, and JG performed analysis of the clinical data. JM, RD, CP, and JS analyzed and interpreted the immune assay data. JC wrote the manuscript. MB, CH, JC, RM, FK, JSt MGM, JS, and JG contributed to overall data interpretation and editing of the manuscript. All authors critically reviewed the manuscript. All authors read and approved the final manuscript.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>This research was supported by the Intramural Research Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Availability of data and materials</title>
              <p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
            </notes>
            <notes>
              <title>Ethics approval and consent to participate</title>
              <p id="Par50">All patients gave written informed consent for participation. This study was approved by the National Cancer Institute Institutional Review Board. The trial national registration number is NCT02536469.</p>
            </notes>
            <notes>
              <title>Consent for publication</title>
              <p id="Par51">Not applicable.</p>
            </notes>
            <notes notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par52">All National Cancer Institute authors declare that they have no competing interests.</p>
              <p id="Par53">Dr. Heery is an employee of Precision Biosciences and has no financial relationship with BMS or this product.</p>
              <p id="Par54">No writing assistance was utilized in the production of this manuscript.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murphy</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Tiffany</surname>
                      <given-names>HL</given-names>
                    </name>
                  </person-group>
                  <article-title>Cloning of complementary DNA encoding a functional human interleukin-8 receptor</article-title>
                  <source>Science.</source>
                  <year>1991</year>
                  <volume>253</volume>
                  <issue>5025</issue>
                  <fpage>1280</fpage>
                  <lpage>1283</lpage>
                  <pub-id pub-id-type="doi">10.1126/science.1891716</pub-id>
                  <pub-id pub-id-type="pmid">1891716</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Holmes</surname>
                      <given-names>WE</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kuang</surname>
                      <given-names>WJ</given-names>
                    </name>
                    <name>
                      <surname>Rice</surname>
                      <given-names>GC</given-names>
                    </name>
                    <name>
                      <surname>Wood</surname>
                      <given-names>WI</given-names>
                    </name>
                  </person-group>
                  <article-title>Structure and functional expression of a human interleukin-8 receptor</article-title>
                  <source>Science.</source>
                  <year>1991</year>
                  <volume>253</volume>
                  <issue>5025</issue>
                  <fpage>1278</fpage>
                  <lpage>1280</lpage>
                  <pub-id pub-id-type="doi">10.1126/science.1840701</pub-id>
                  <pub-id pub-id-type="pmid">1840701</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Waugh</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Wilson</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>The interleukin-8 pathway in cancer</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2008</year>
                  <volume>14</volume>
                  <issue>21</issue>
                  <fpage>6735</fpage>
                  <lpage>6741</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4843</pub-id>
                  <pub-id pub-id-type="pmid">18980965</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gabellini</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Trisciuoglio</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Desideri</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Candiloro</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ragazzoni</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Orlandi</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression</article-title>
                  <source>Eur J Cancer</source>
                  <year>2009</year>
                  <volume>45</volume>
                  <issue>14</issue>
                  <fpage>2618</fpage>
                  <lpage>2627</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejca.2009.07.007</pub-id>
                  <pub-id pub-id-type="pmid">19683430</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brat</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Bellail</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Van Meir</surname>
                      <given-names>EG</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis</article-title>
                  <source>Neuro-Oncology</source>
                  <year>2005</year>
                  <volume>7</volume>
                  <issue>2</issue>
                  <fpage>122</fpage>
                  <lpage>133</lpage>
                  <pub-id pub-id-type="doi">10.1215/S1152851704001061</pub-id>
                  <pub-id pub-id-type="pmid">15831231</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Maxwell</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Gallagher</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Seaton</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Wilson</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Scullin</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Pettigrew</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells</article-title>
                  <source>Oncogene.</source>
                  <year>2007</year>
                  <volume>26</volume>
                  <issue>52</issue>
                  <fpage>7333</fpage>
                  <lpage>7345</lpage>
                  <pub-id pub-id-type="doi">10.1038/sj.onc.1210536</pub-id>
                  <pub-id pub-id-type="pmid">17533374</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Skov</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Beurskens</surname>
                      <given-names>FJ</given-names>
                    </name>
                    <name>
                      <surname>Zachariae</surname>
                      <given-names>CO</given-names>
                    </name>
                    <name>
                      <surname>Reitamo</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Teeling</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Satijn</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis</article-title>
                  <source>J Immunol</source>
                  <year>2008</year>
                  <volume>181</volume>
                  <issue>1</issue>
                  <fpage>669</fpage>
                  <lpage>679</lpage>
                  <pub-id pub-id-type="doi">10.4049/jimmunol.181.1.669</pub-id>
                  <pub-id pub-id-type="pmid">18566434</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yoshimura</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Matsushima</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Oppenheim</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Leonard</surname>
                      <given-names>EJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1)</article-title>
                  <source>J Immunol</source>
                  <year>1987</year>
                  <volume>139</volume>
                  <issue>3</issue>
                  <fpage>788</fpage>
                  <lpage>793</lpage>
                  <?supplied-pmid 3298433?>
                  <pub-id pub-id-type="pmid">3298433</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Yao</surname>
                      <given-names>PL</given-names>
                    </name>
                    <name>
                      <surname>Yuan</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Hong</surname>
                      <given-names>TM</given-names>
                    </name>
                    <name>
                      <surname>Shun</surname>
                      <given-names>CT</given-names>
                    </name>
                    <name>
                      <surname>Kuo</surname>
                      <given-names>ML</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2003</year>
                  <volume>9</volume>
                  <issue>2</issue>
                  <fpage>729</fpage>
                  <lpage>737</lpage>
                  <?supplied-pmid 12576442?>
                  <pub-id pub-id-type="pmid">12576442</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Freund</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Chauveau</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Brouillet</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Lucas</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Lacroix</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Licznar</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells</article-title>
                  <source>Oncogene.</source>
                  <year>2003</year>
                  <volume>22</volume>
                  <issue>2</issue>
                  <fpage>256</fpage>
                  <lpage>265</lpage>
                  <pub-id pub-id-type="doi">10.1038/sj.onc.1206113</pub-id>
                  <pub-id pub-id-type="pmid">12527894</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ning</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Manegold</surname>
                      <given-names>PC</given-names>
                    </name>
                    <name>
                      <surname>Hong</surname>
                      <given-names>YK</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Pohl</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Lurje</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models</article-title>
                  <source>Int J Cancer</source>
                  <year>2011</year>
                  <volume>128</volume>
                  <issue>9</issue>
                  <fpage>2038</fpage>
                  <lpage>2049</lpage>
                  <pub-id pub-id-type="doi">10.1002/ijc.25562</pub-id>
                  <pub-id pub-id-type="pmid">20648559</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fujimoto</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sakaguchi</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Aoki</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Tamaya</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers</article-title>
                  <source>Cancer Res</source>
                  <year>2000</year>
                  <volume>60</volume>
                  <issue>10</issue>
                  <fpage>2632</fpage>
                  <lpage>2635</lpage>
                  <?supplied-pmid 10825134?>
                  <pub-id pub-id-type="pmid">10825134</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kitadai</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Haruma</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Sumii</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Yamamoto</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ue</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Yokozaki</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Expression of interleukin-8 correlates with vascularity in human gastric carcinomas</article-title>
                  <source>Am J Pathol</source>
                  <year>1998</year>
                  <volume>152</volume>
                  <issue>1</issue>
                  <fpage>93</fpage>
                  <lpage>100</lpage>
                  <?supplied-pmid 9422527?>
                  <pub-id pub-id-type="pmid">9422527</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xie</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Interleukin-8 and human cancer biology</article-title>
                  <source>Cytokine Growth Factor Rev</source>
                  <year>2001</year>
                  <volume>12</volume>
                  <issue>4</issue>
                  <fpage>375</fpage>
                  <lpage>391</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1359-6101(01)00016-8</pub-id>
                  <pub-id pub-id-type="pmid">11544106</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sanmamed</surname>
                      <given-names>MF</given-names>
                    </name>
                    <name>
                      <surname>Carranza-Rua</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Alfaro</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Onate</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Martin-Algarra</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Perez</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2014</year>
                  <volume>20</volume>
                  <issue>22</issue>
                  <fpage>5697</fpage>
                  <lpage>5707</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-3203</pub-id>
                  <pub-id pub-id-type="pmid">25224278</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Charafe-Jauffret</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Ginestier</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Iovino</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Wicinski</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Cervera</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Finetti</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature</article-title>
                  <source>Cancer Res</source>
                  <year>2009</year>
                  <volume>69</volume>
                  <issue>4</issue>
                  <fpage>1302</fpage>
                  <lpage>1313</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2741</pub-id>
                  <pub-id pub-id-type="pmid">19190339</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Highfill</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Cui</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Giles</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Morse</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy</article-title>
                  <source>Sci Transl Med</source>
                  <year>2014</year>
                  <volume>6</volume>
                  <issue>237</issue>
                  <fpage>237ra67</fpage>
                  <pub-id pub-id-type="doi">10.1126/scitranslmed.3007974</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Roselli</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Fernando</surname>
                      <given-names>RI</given-names>
                    </name>
                    <name>
                      <surname>Guadagni</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Spila</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Alessandroni</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Palmirotta</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2012</year>
                  <volume>18</volume>
                  <issue>14</issue>
                  <fpage>3868</fpage>
                  <lpage>3879</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-3211</pub-id>
                  <pub-id pub-id-type="pmid">22611028</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <mixed-citation publication-type="other">Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, et al. Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis. J Natl Cancer Inst. 2014;106(5). 10.1093/jnci/dju054.</mixed-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Palena</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>DH</given-names>
                    </name>
                    <name>
                      <surname>Fernando</surname>
                      <given-names>RI</given-names>
                    </name>
                  </person-group>
                  <article-title>Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment</article-title>
                  <source>Future Oncol</source>
                  <year>2012</year>
                  <volume>8</volume>
                  <issue>6</issue>
                  <fpage>713</fpage>
                  <lpage>722</lpage>
                  <pub-id pub-id-type="doi">10.2217/fon.12.59</pub-id>
                  <pub-id pub-id-type="pmid">22764769</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Conroy</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kruyt</surname>
                      <given-names>FAE</given-names>
                    </name>
                    <name>
                      <surname>Wagemakers</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bhat</surname>
                      <given-names>KPL</given-names>
                    </name>
                    <name>
                      <surname>den Dunnen</surname>
                      <given-names>WFA</given-names>
                    </name>
                  </person-group>
                  <article-title>IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma</article-title>
                  <source>Oncotarget.</source>
                  <year>2018</year>
                  <volume>9</volume>
                  <issue>21</issue>
                  <fpage>15721</fpage>
                  <lpage>15731</lpage>
                  <pub-id pub-id-type="doi">10.18632/oncotarget.24595</pub-id>
                  <pub-id pub-id-type="pmid">29644004</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>David</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Dominguez</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>DH</given-names>
                    </name>
                    <name>
                      <surname>Palena</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>The IL-8/IL-8R Axis: a double agent in tumor immune resistance</article-title>
                  <source>Vaccines.</source>
                  <year>2016</year>
                  <volume>4</volume>
                  <issue>3</issue>
                  <fpage>22</fpage>
                  <pub-id pub-id-type="doi">10.3390/vaccines4030022</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fernando</surname>
                      <given-names>RI</given-names>
                    </name>
                    <name>
                      <surname>Castillo</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Litzinger</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>DH</given-names>
                    </name>
                    <name>
                      <surname>Palena</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells</article-title>
                  <source>Cancer Res</source>
                  <year>2011</year>
                  <volume>71</volume>
                  <issue>15</issue>
                  <fpage>5296</fpage>
                  <lpage>5306</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-0156</pub-id>
                  <pub-id pub-id-type="pmid">21653678</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huang</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Fernando</surname>
                      <given-names>RI</given-names>
                    </name>
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>DH</given-names>
                    </name>
                    <name>
                      <surname>Litzinger</surname>
                      <given-names>MT</given-names>
                    </name>
                    <name>
                      <surname>Hodge</surname>
                      <given-names>JW</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies</article-title>
                  <source>Cell Death Dis</source>
                  <year>2013</year>
                  <volume>4</volume>
                  <fpage>e682</fpage>
                  <pub-id pub-id-type="doi">10.1038/cddis.2013.208</pub-id>
                  <pub-id pub-id-type="pmid">23788039</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Larocca</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Fernando</surname>
                      <given-names>RI</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>DH</given-names>
                    </name>
                    <name>
                      <surname>Palena</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>An autocrine loop between TGF-beta1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype</article-title>
                  <source>Mol Cancer Ther</source>
                  <year>2013</year>
                  <volume>12</volume>
                  <issue>9</issue>
                  <fpage>1805</fpage>
                  <lpage>1815</lpage>
                  <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-1007</pub-id>
                  <pub-id pub-id-type="pmid">23783250</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>DH</given-names>
                    </name>
                    <name>
                      <surname>Litzinger</surname>
                      <given-names>MT</given-names>
                    </name>
                    <name>
                      <surname>Fernando</surname>
                      <given-names>RI</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Palena</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas</article-title>
                  <source>Semin Oncol</source>
                  <year>2012</year>
                  <volume>39</volume>
                  <issue>3</issue>
                  <fpage>358</fpage>
                  <lpage>366</lpage>
                  <pub-id pub-id-type="doi">10.1053/j.seminoncol.2012.02.005</pub-id>
                  <pub-id pub-id-type="pmid">22595058</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dominguez</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>McCampbell</surname>
                      <given-names>KK</given-names>
                    </name>
                    <name>
                      <surname>David</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Palena</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer</article-title>
                  <source>JCI Insight</source>
                  <year>2017</year>
                  <volume>2</volume>
                  <issue>21</issue>
                  <fpage>e94296</fpage>
                  <pub-id pub-id-type="doi">10.1172/jci.insight.94296</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Eisenhauer</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Therasse</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Bogaerts</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>LH</given-names>
                    </name>
                    <name>
                      <surname>Sargent</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Ford</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title>
                  <source>Eur J Cancer</source>
                  <year>2009</year>
                  <volume>45</volume>
                  <issue>2</issue>
                  <fpage>228</fpage>
                  <lpage>247</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id>
                  <pub-id pub-id-type="pmid">19097774</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sanmamed</surname>
                      <given-names>MF</given-names>
                    </name>
                    <name>
                      <surname>Perez-Gracia</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Schalper</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Fusco</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Gonzalez</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Rodriguez-Ruiz</surname>
                      <given-names>ME</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients</article-title>
                  <source>Ann Oncol</source>
                  <year>2017</year>
                  <volume>28</volume>
                  <issue>8</issue>
                  <fpage>1988</fpage>
                  <lpage>1995</lpage>
                  <pub-id pub-id-type="doi">10.1093/annonc/mdx190</pub-id>
                  <pub-id pub-id-type="pmid">28595336</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Seaton</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Scullin</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Maxwell</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Wilson</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Pettigrew</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gallagher</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation</article-title>
                  <source>Carcinogenesis.</source>
                  <year>2008</year>
                  <volume>29</volume>
                  <issue>6</issue>
                  <fpage>1148</fpage>
                  <lpage>1156</lpage>
                  <pub-id pub-id-type="doi">10.1093/carcin/bgn109</pub-id>
                  <pub-id pub-id-type="pmid">18487223</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bangsgaard</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Houtkamp</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Schuurhuis</surname>
                      <given-names>DH</given-names>
                    </name>
                    <name>
                      <surname>Parren</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Baadsgaard</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Niessen</surname>
                      <given-names>HW</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor</article-title>
                  <source>PLoS One</source>
                  <year>2012</year>
                  <volume>7</volume>
                  <issue>6</issue>
                  <fpage>e39706</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0039706</pub-id>
                  <pub-id pub-id-type="pmid">22761877</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
